Regulatory Role of Inflammatory and Pro-Inflammatory Cytokines in Rheumatoid Arthritis: Mechanisms and Therapeutic Insights

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent synovial inflammation, joint destruction, and systemic complications. The dysregulation of inflammatory and pro-inflammatory cytokines plays a pivotal role in RA pathogenesis by promoting immune cell activation, synovial hyperplasia, and osteoclast genesis. Key cytokines such as tumour necrosis factor-alpha (TNF-?), interleukin-1 (IL-1), IL-6, and IL-17 contribute to disease progression, while regulatory cytokines like IL-10, IL-4, and transforming growth factor-beta (TGF-?) attempt to mitigate inflammation. Cytokine-targeted therapies, including TNF inhibitors, IL-6 receptor antagonists, JAK-STAT inhibitors, and emerging biologics, have transformed RA treatment by modulating immune responses. However, challenges such as drug resistance, heterogeneous patient responses, and long-term safety concerns necessitate further research. Future directions emphasize personalized medicine, novel cytokine targets, gene therapy, and advanced drug delivery systems to optimize therapeutic efficacy and improve patient outcomes. This review provides insights into the mechanisms of cytokine-mediated inflammation and the evolving landscape of cytokine-based therapies for RA management.

Keywords

Introduction

Table-1: Therapeutic Targeting of Cytokine Pathways:

1.1.  Regulatory Role of Cytokines in Rheumatoid Arthritis (RA) Pathogenesis

Fig.1. Currently, seven anti-cytokine drugs are approved. Five of them – infliximab, adalimumab, golimumab, certolizumab-pegol, and etanercept – target TNFa[11]. Two others block next top pro-inflammatory cytokines: anakinra – IL-1b, tocilizumab – IL-6. According to Pharmaceutical Research and Manufacturers of America there were 55 new drugs for RA treatment tested in USA in 2014[12]. Sarilumab and sarilumab – anti-IL-6 molecules – and canakinumab, which blocks IL-1b belong to bard under development. Other drugs (AMG 714 – anti-IL-15, denosumab – anti-RANKL, afelimomab, eculizumab, and broadloom – anti-IL-17) target diverse cytokines, which impact has been proved in RA pathogenesis.                                     

1.2. Key Inflammatory and Pro-Inflammatory Cytokines in RA

Pro-Inflammatory Cytokines:

Tumour Necrosis Factor-alpha (TNF-α)

TNF-α is a pivotal cytokine in RA pathophysiology, driving inflammation by inducing the production of other cytokines (e.g., IL-1, IL-6), upregulating adhesion molecules, and promoting osteoclast genesis[13]. TNF-α inhibitors such as infliximab and adalimumab have demonstrated significant efficacy in reducing disease activity.

TNF-α in RA Pathogenesis includes,

• Central to RA pathogenesis.
• Promotes inflammation by stimulating synovial fibroblasts, macrophages, and osteoclasts[14].
• Induces production of other pro-inflammatory cytokines (IL-1, IL-6).
• Leads to cartilage and bone destruction.
• Targeted by biologics like infliximab, etanercept, and adalimumab[15].

Primary Function: TNF-α is a master cytokine in RA, driving synovial inflammation, angiogenesis, and joint destruction. The Regulation is based on, the TNF-α is controlled by endogenous inhibitors such as soluble TNF receptors (sTNFRs), which bind excess TNF-α and prevent it from engaging membrane-bound TNF receptors. The IL-10 and TGF-β can downregulate TNF-α production by inhibiting macrophage activation[16].

Interleukin-1 (IL-1)

IL-1, particularly IL-1β, contributes to synovial inflammation by enhancing fibroblast-like synovectomy (FLS) proliferation, inducing matrix metalloproteinases (MMPs), and stimulating osteoclast differentiation. IL-1 receptor antagonists like anakinra have been developed as targeted therapies to mitigate its effects[17].

IL-1 in RA Pathogenesis includes,

• Enhances synovial inflammation.
• Promotes cartilage degradation by increasing matrix metalloproteinases (MMPs).
• Stimulates osteoclast activation, leading to bone erosion[18].
• Blocked by anakinra (IL-1 receptor antagonist).

Interleukin-6 (IL-6)

IL-6 is involved in acute phase response modulation, B cell differentiation, and T cell activation. It contributes to systemic RA symptoms such as fatigue and anaemia. IL-6 inhibitors like tocilizumab have shown efficacy in patients who are refractory to TNF-α inhibitors[19].

IL-6 in RA Pathogenesis includes,

• Involved in systemic and local inflammation.
• Promotes B-cell differentiation, autoantibody production, and T-cell activation.
• Contributes to joint destruction and systemic effects (fatigue, anaemia)[20].
• Targeted by tocilizumab and sarilumab (IL-6 receptor inhibitors).

The Primary Function of IL-6 is Drives synovial inflammation, systemic effects (fatigue, anaemia), and B-cell differentiation[21]. The Regulation is based on the Suppressor of cytokine signalling (SOCS) proteins, particularly SOCS3, inhibit IL-6 signalling by blocking the JAK-STAT pathway. The IL-10 also downregulates IL-6 production[22].

Interleukin-17 (IL-17)

IL-17, predominantly produced by Th17 cells, promotes neutrophil recruitment and enhances the production of pro-inflammatory mediators[23]. IL-17 blockade using agents like eculizumab has been explored for managing refractory RA cases.

IL-17 in RA Pathogenesis includes,

• Produced by Th17 cells.
• Stimulates synovial fibroblasts and osteoclasts, leading to tissue destruction.
• Synergizes with TNF-α and IL-1 to worsen inflammation[24].
• Targeted by eculizumab and afelimomab (IL-17 inhibitors, though primarily for psoriasis and spondylarthritis rather than RA).
• Regulation: IL-4 and IL-10 suppress Th17 differentiation, reducing IL-17 levels and Treg cells (via Foxp3 expression) inhibit Th17-mediated inflammation[25].

1.3.Anti-Inflammatory Cytokines:

Interleukin-10 (IL-10): The Anti-Inflammatory Cytokines IL-10 Inhibits pro-inflammatory cytokines (TNF-α, IL-1, IL-6) and Promotes regulatory T-cell (Treg) function and Reduces macrophage activation[26]. The Source of IL-10 is Produced by regulatory T cells (Tregs), macrophages, and B cells. The Functions which including, Inhibits pro-inflammatory cytokines such as TNF-α, IL-1, IL-6 and Downregulates antigen presentation and co-stimulation of T cells and also Reduces macrophage activation and prevents synovial hyperplasia. Regulatory Mechanism in RA: IL-10 induces SOCS proteins, which inhibit pro-inflammatory signalling[27]. IL-10 suppresses nuclear factor-κB (NF-κB), a key transcription factor for inflammatory cytokines. Despite its protective effects, IL-10 levels are often insufficient in RA, leading to unchecked inflammation[28].

Interleukin-4 (IL-4) and Interleukin-13 (IL-13): which Promote M2 (anti-inflammatory) macrophage activation and Inhibit Th1/Th17 differentiation and also Shift immune balance towards resolution of inflammation.

JAK-STAT Pathway and Targeted Inhibition: Janus kinase (JAK) signalling mediates cytokine-induced inflammation in RA[29]. JAK inhibitors (tofacitinib, baricitinib, Upadacitinib) block JAK1/JAK3 or JAK2 pathways, reducing cytokine-driven inflammation.

Transforming Growth Factor-beta (TGF-β): The Source: Secreted by Tregs, synovial fibroblasts, and chondrocytes. The Functions which including, Promotes immune tolerance by inducing Foxp3+ Tregs[30]. Suppresses pro-inflammatory Th1 and Th17 responses. Regulates synovial fibroblast proliferation and limits joint destruction.

Paradox in RA: While TGF-β is generally anti-inflammatory, it can promote fibrosis and synovial hyperplasia in the RA joint under certain conditions[31].

IL-27 – A Dual Role Cytokine: The Source is Produced by antigen-presenting cells (APCs). The Regulatory Function of these including, Suppresses Th17 responses and enhances Treg differentiation[32]. Inhibits synovial inflammation by reducing IL-6 and IL-17 production. Potential as a Therapeutic Target: IL-27 agonists may help restore immune balance in RA.

1.4.Regulatory Failure and Chronic Inflammation in RA

Imbalance Between Pro- and Anti-Inflammatory Cytokines: Insufficient IL-10 and TGF-β fail to counteract TNF-α, IL-6, and IL-17. Defective Treg function leads to excessive Th1/Th17-driven inflammation. Epigenetic Modifications in RA Synovium: Methylation changes alter cytokine expression, shifting towards a pro-inflammatory profile[33]. Autoimmune Amplification Loop: Chronic antigen presentation (via dendritic cells and B cells) sustains cytokine-driven inflammation[34].

1.5. Restoring Cytokine Balance as a Therapeutic Goal

Understanding the regulatory role of cytokines in RA highlights the complexity of immune modulation in disease pathogenesis. While current therapies target key inflammatory pathways (TNF-α, IL-6, IL-17, and JAK-STAT), future strategies may focus on enhancing regulatory cytokines (IL-10, IL-4, IL-27) to restore immune homeostasis[35].

1.6.Mech anises of Cytokine-Mediated Inflammation

Pro-inflammatory cytokines in RA contribute to disease progression through several mechanisms: which including, Activation of Immune Cells: Cytokines stimulate T cells, B cells, and macrophages, perpetuating the inflammatory cycle[36]. Synovial Fibroblast Proliferation: Fibroblast-like nonadipocytes (FLS) in RA display aggressive phenotypes, producing MMPs that degrade cartilage and bone. Osteoclast genesis: Cytokines like TNF-α, IL-1, and IL-6 induce receptor activator of nuclear factor kappa-B ligand (RANKL), promoting osteoclast differentiation and bone resorption[37]. Mechanisms of Cytokine-Driven Pathogenesis in RA: which includes, Macrophage and Fibroblast Activation’s-α and IL-6 activate synovial macrophages and fibroblast-like nonadipocytes (FLS), leading to increased inflammatory mediators. T-Cell and B-Cell Interaction: IL-6 and IL-21 promote B-cell differentiation and autoantibody (e.g., RF, ACPA) production. IL-17 and IL-23 drive Th17 expansion, increasing tissue inflammation. Osteoclast Activation and Bone Erosion: TNF-α, IL-1, and IL-17 enhance RANKL expression, leading to osteoclast differentiation and bone resorption. Cartilage Degradation: IL-1 and TNF-α upregulate matrix metalloproteinases (MMPs), which degrade extracellular matrix and cartilage[38]. Systemic Effects: IL-6 drives acute-phase response (e.g., increased CRP, anaemia, fatigue). Chronic inflammation contributes to cardiovascular and metabolic comorbidities in RA.

1.7. Therapeutic Insights and Future Directions in Cytokine-Targeted Therapy for RA

The understanding of cytokine pathways in rheumatoid arthritis (RA) has revolutionized treatment, leading to the development of biologics and targeted small molecules. However, challenges such as heterogeneous patient responses, drug resistance, and long-term safety concerns remain. Future directions focus on personalized therapy, combination strategies, novel cytokine targets, and immune modulation approaches[39].

2.Current Cytokine-Targeted Therapies in RA

A. TNF-α Inhibitors (Anti-TNF Biologics)

Drugs: Infliximab (Remicade), Adalimumab (Humira), Etanercept (Enbrel), Golimumab (Simponi), Certolizumab pegol (Cimzia). The Mechanism is Neutralize TNF-α, preventing activation of pro-inflammatory pathways. The Limitations for this including, ~30% of RA patients show inadequate response. Risk of infections (e.g., tuberculosis, fungal infections). Long-term use associated with potential malignancy risk[40]. The Future Considerations includes, Combination with JAK inhibitors to improve response in refractory patients. Personalized biomarkers (e.g., TNF gene polymorphisms) to predict efficacy.

B. IL-6 Inhibitors

Drugs: Tocilizumab (Actemra) – IL-6 receptor inhibitor. Sarilumab (Kevzara) – IL-6 receptor inhibitor. Mechanism: Blocks IL-6 signalling, reducing systemic inflammation (e.g., fatigue, anaemia). Limitations: Increased risk of infections. Elevated cholesterol and cardiovascular risks. Future Directions: Oral IL-6 inhibitors under investigation to improve patient adherence[41]. Dual IL-6 and JAK blockade for enhanced control of refractory RA.

C. IL-1 Inhibition

Drug: Anakinra (Kineret) – IL-1 receptor antagonist. Limitations: Less effective than TNF-α inhibitors; rarely used in RA. Future Approach: Gene therapy-based IL-1Ra overexpression in joint tissues.

D. JAK-STAT Pathway Inhibitors (JAK Inhibitors)

Drugs: Tofacitinib (Xeljanz) – JAK1/JAK3 inhibitor, Baricitinib (Olumiant) – JAK1/JAK2 inhibitor, Upadacitinib (Rino) – JAK1 selective inhibitor, Nilotinib – JAK1 selective inhibitor (under evaluation).

Mechanism: Inhibit cytokine signalling via the JAK-STAT pathway.

Advantages Over Biologics: Oral administration – improves compliance[42]. Rapid onset of action compared to biologics.

Limitations: Risk of thrombosis, infections, and malignancy (FDA issued a warning for tofacitinib).

Future Strategies: Selective TYK2 inhibition (newer JAK family member with fewer side effects). Combination with biologics for resistant cases.

3. Future Directions: Emerging Cytokine Targets in RA

A. IL-17 and IL-23 Inhibitors

IL-17 and IL-23 drive Th17-mediated inflammation, leading to joint damage. IL-17 inhibitors (eculizumab, afelimomab) are effective in psoriatic arthritis but not RA – reasons are still unclear.

Future Strategy: Targeting IL-23 (rusalka) in early RA to block Th17 differentiation[43]. Dual IL-17/IL-6 blockade in aggressive RA subtypes.

B. IL-10 Therapy – Boosting Regulatory Cytokines

IL-10 suppresses TNF-α, IL-1, and IL-6, but its systemic administration has failed in trials due to paradoxical immune activation. Future Strategy: Gene therapy: Delivering IL-10 locally to inflamed joints. Nanoparticle-based IL-10 delivery to enhance stability[44].

C. GM-CSF Inhibitors – Targeting Macrophage Activation

GM-CSF drives macrophage activation, synovial inflammation, and pain. Drugs under development: Sarilumab (anti-GM-CSF antibody), Otilia – Phase III trials. Potential Benefits: Reducing macrophage-driven pain and inflammation. Might be effective in RA patients resistant to TNF inhibitors[45].

3. 1Personalized and Precision Medicine in RA

A. Biomarker-Driven Therapy

Current RA treatment is trial-and-error, leading to delays in effective therapy. Potential biomarkers for therapy selection: Serum TNF levels – predict response to TNF inhibitors. IL-6 gene polymorphisms – guide IL-6 inhibitor use. JAK-STAT mutations – predict JAK inhibitor efficacy[46].

Future Approach: AI-based machine learning models to predict best therapy based on genetic, immune, and clinical data.

B. Epigenetic Modulation as a Future Strategy

Histone modifications and DNA methylation regulate cytokine production in Prepotentials therapies: HDAC inhibitors (e.g., galvanostatic) to suppress inflammatory genes[47]. DNA methylation-targeting drugs to restore immune tolerance.

3.2. Combination and Sequential Therapies for RA

A. TNF Inhibitor + JAK Inhibitor Combination

Rationale:

• TNF inhibitors block acute inflammation.
• JAK inhibitors suppress chronic cytokine signalling.
• Challenge: Increased infection risk.

B. Sequential Targeted Therapy

Some patients lose response to biologics over time. Future approach: Switching between cytokine blockers based on immune profiling (e.g., TNF → IL-6 → JAK inhibition). Tapering therapy once remission is achieved to reduce long-term risks[48].

3.3 Novel Drug Delivery Approaches

A. Nanotechnology for Cytokine Inhibition

Goal: Deliver cytokine inhibitors directly to inflamed joints, reducing systemic side effects. Potential Strategies: Nanoparticle-loaded TNF inhibitors for local release[49]. CRISPR-based cytokine suppression to selectively edit immune cells.

B. mRNA Therapy for Cytokine Modulation

mRNA-based cytokine blockers (similar to COVID-19 vaccines) could offer precise control over cytokine levels[50]. Example: mRNA encoding soluble TNF receptors to neutralize TNF-α dynamically.

3. 4. Future Directions

Targeting pro-inflammatory cytokines has revolutionized RA treatment[51]. However, challenges such as drug resistance, adverse effects, and incomplete remission necessitate ongoing research. Future directions include:

• Personalized Medicine: Identifying cytokine profiles in patients to tailor specific treatments [52].
• Combination Therapies: Using multi-target approaches to enhance efficacy and reduce resistance.
• Novel Biologics and Small Molecules: Developing new inhibitors for emerging cytokine pathways [53].

CONCLUSION

Inflammatory and pro-inflammatory cytokines play a central role in RA pathogenesis. Advances in cytokine-targeted therapies have significantly improved patient outcomes, yet further research is required to optimize treatment strategies and address unmet clinical needs. Rheumatoid arthritis (RA) is a chronic autoimmune disease driven by a complex interplay of inflammatory and pro-inflammatory cytokines that perpetuate joint inflammation, synovial hyperplasia, and tissue destruction. Cytokines such as TNF-α, IL-1β, IL-6, and IL-17 are central mediators of the disease process, while regulatory cytokines like IL-10 and TGF-β attempt to counterbalance inflammation. Advances in understanding the signalling pathways and cellular sources of these cytokines have led to significant therapeutic breakthroughs, particularly with biologics and small molecule inhibitors targeting specific cytokines and their receptors. Despite the success of these therapies, challenges such as drug resistance, partial remission, and disease heterogeneity remain. Future strategies aim to personalize cytokine-targeted therapies and restore immune tolerance, offering the potential for more effective and long-lasting control of RA

REFERENCES

1. Feldmann M, Maini RN. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev. 2008;223:7–19.
2. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440.
3. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, Barrera P, van de Loo FA, Dinarello CA, van den Berg WB. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2006;103(9):3298–3303.
4. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, Barrera P, van de Loo FA, Dinarello CA, van den Berg WB. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2006;103(9):3298–3303.
5. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440.
6. Feldmann M, Maini RN. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev. 2008;223:7–19.
7. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, Barrera P, van de Loo FA, Dinarello CA, van den Berg WB. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2006;103(9):3298–3303.
8. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, Barrera P, van de Loo FA, Dinarello CA, van den Berg WB. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2006;103(9):3298–3303.
9. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440.
10. Feldmann M, Maini RN. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev. 2008;223:7–19.
11. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, Barrera P, van de Loo FA, Dinarello CA, van den Berg WB. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2006;103(9):3298–3303.
12. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, Barrera P, van de Loo FA, Dinarello CA, van den Berg WB. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2006;103(9):3298–3303.
13. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440.
14. Feldmann M, Maini RN. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev. 2008;223:7–19.
15. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, Barrera P, van de Loo FA, Dinarello CA, van den Berg WB. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2006;103(9):3298–3303.
16. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, Barrera P, van de Loo FA, Dinarello CA, van den Berg WB. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2006;103(9):3298–3303.
17. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397–440.
18. I.B. McInnes, G. Schett, The pathogenesis of rheumatoid arthritis, N Engl J Med 365 (23) (2011) 2205–2219.
19. C. Selmi, E. Generali, M. Massarotti, G. Bianchi, C.A. Sciré, New treatments for inflammatory rheumatic disease, Immunol Res 60 (2–3) (2014) 277–288.
20. B. Astry, E. Harberts, K.D. Moudgil, A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis, J Interferon Cytokine Res 31 (12) (2011) 927–940.
21. G.S. Firestein, Evolving concepts of rheumatoid arthritis, Nature 423 (6937) (2003) 356–361.
22. J. Davis, in: E. Matteson (Ed.), Cytokine biomarkers and the promise of personalized therapy in rheumatoid arthritis, vol. 5, Reumatologia Clinica, Rochester, Minnesote, 2009, pp. 143–146.
23. F.M. Brennan, I.B. McInnes, Evidence that cytokines play a role in rheumatoid arthritis, J Clin Invest 118 (11) (2008) 3537–3545.
24. D. Aletaha, T. Neogi, A.J. Silman, J. Funovits, D.T. Felson, C.O. Bingham, N.S. Birnbaum, G.R. Burmester, V.P. Bykerk, M.D. Cohen, et al., Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative, Arthritis Rheum 62 (9) (2010) 2569–2581.
25. J.S. Smolen, D. Aletaha, J. Grisar, K. Redlich, G. Steiner, O. Wagner, The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?, Arthritis Res Ther 10 (3) (2008) 208
26. S. Bas, T.V. Perneger, M. Seitz, J.M. Tiercy, P. Roux-Lombard, P.A. Guerne, Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors, Rheumatology (Oxford) 41 (7) (2002) 809–814.
27. M. Haque, K. Fino, F. Lei, X. Xiong, J. Song, Utilizing regulatory T cells against rheumatoid arthritis, Front Oncol 4 (2014) 209.
28. K.D. Deane, Preclinical rheumatoid arthritis (autoantibodies): an updated review, Curr Rheumatol Rep 16 (5) (2014) 419.
29. G.S. Firestein, The disease formerly known as rheumatoid arthritis, Arthritis Res Ther 16 (3) (2014) 114.
30. H.R. Kim, Anti-citrullinated protein antibodies in rheumatoid arthritis: a bridge between genetic predisposition and autoimmunity, Korean J Intern Med 28 (1) (2013) 25–28.
31.  A.Kosmaczewska, J. Swierkot, L. Ciszak, A. Szteblich, A. Chrobak, L. Karabon, A. Partyka, J. Szechinski, P. Wiland, I. Frydecka, Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment despite clinical improvement, Rheumatol Int 34 (2) (2014) 243– 253.
32. A.P. Cope, T cells in rheumatoid arthritis, Arthritis Res Ther 10 (suppl 1) (2008) S1. N. Komatsu, H. Takayanagi, Arthritogenic T cells in autoimmune arthritis, Int J Biochem Cell Biol 58 (2015) 92–96.
33. J. Paw?owska, _ Z. Smolen´ ska, J. Witkowski, E.M. Bryl, Different pattern of T-cell subpopulations in peripheral blood of patients with rheumatoid arthritis at various stages of disease development, Pol Arch Med Wewn 124 (1–2) (2014) 43–50.
34. Z. Smolen´ ska, J. Paw?owska, A. Daca, M. Soroczyn´ ska-Cybula, J. Witkowski, E. M. Bryl, Disease activity in patients with long-lasting rheumatoid arthritis is associated with changes in peripheral blood lymphocyte subpopulations, Pol Arch Med Wewn 122 (12) (2012) 591–598.
35. C. Chizzolini, J.M. Dayer, P. Miossec, Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance?, Arthritis Res Ther 11 (5) (2009) 246
36. J.A. Stenken, A.J. Poschenrieder, Bioanalytical chemistry of cytokines – a review, Anal Chim Acta 853 (2015) 95–115.
37. M.J. Vervoordeldonk, P.P. Tak, Cytokines in rheumatoid arthritis, Curr Rheumatol Rep 4 (3) (2002) 208–217.
38. L. Zhang, J.M. Li, X.G. Liu, D.X. Ma, N.W. Hu, Y.G. Li, W. Li, Y. Hu, S. Yu, X. Qu, et al., Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis, J Clin Immunol 31 (4) (2011) 606–614.
39. R. Gerli, O. Bistoni, A. Russano, S. Fiorucci, L. Borgato, M.E. Cesarotti, C. Lunardi, In vivo activated T cells in rheumatoid synovitis. Analysis of Th1- and Th2-type cytokine production at clonal level in different stages of disease, Clin Exp Immunol 129 (3) (2002) 549–555.
40. P. Miossec, W. van den Berg, Th1/Th2 cytokine balance in arthritis, Arthritis Rheum 40 (12) (1997) 2105–2115. C.A. Dinarello, Proinflammatory cytokines, Chest 118 (2) (2000) 503–508.
41. V. Tayal, B.S. Kalra, Cytokines and anti-cytokines as therapeutics – an update, Eur J Pharmacol 579 (1–3) (2008) 1–12.
42. P.W. Meyer, B. Hodkinson, M. Ally, E. Musenge, A.A. Wadee, H. Fickl, M. Tikly, R. Anderson, Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis, Mediators Inflamm 2010 (2010) 158514.
43. G. Steiner, M. Tohidast-Akrad, G. Witzmann, M. Vesely, A. Studnicka-Benke, A. Gal, M. Kunaver, P. Zenz, J.S. Smolen, Cytokine production by synovial T cells in rheumatoid arthritis, Rheumatology (Oxford) 38 (3) (1999) 202–213.
44. C. Monaco, J. Nanchahal, P. Taylor, M. Feldmann, Anti-TNF therapy: past, present and future, Int Immunol 27 (1) (2015) 55–62.
45. K. Nozawa, M. Fujishiro, Y. Takasaki, I. Sekigawa, Inhibition of rheumatoid arthritis by blocking connective tissue growth factor, World J Orthop 5 (5) (2014) 653–659.
46. J.S. Smolen, D. Aletaha, M. Koeller, M.H. Weisman, P. Emery, New therapies for treatment of rheumatoid arthritis, Lancet 370 (9602) (2007) 1861– 1874.
47. J.A. Singh, R. Christensen, G.A. Wells, M.E. Suarez-Almazor, R. Buchbinder, M.A. Lopez-Olivo, E.T. Ghogomu, P. Tugwell, A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview, CMAJ 181 (11) (2009) 787–796.
48. S. Nadkarni, C. Mauri, M.R. Ehrenstein, Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta, J Exp Med 204 (1) (2007) 33–39.
49. S. Tukaj, A. Kotlarz, A. Józ´wik, Z. Smolen´ ska, E. Bryl, J.M. Witkowski, B. Lipin´ ska, Cytokines of the Th1 and Th2 type in sera of rheumatoid arthritis patients; correlations with anti-Hsp40 immune response and diagnostic markers, Acta Biochim Pol 57 (3) (2010) 327–332.
50. B. Afzali, G. Lombardi, R.I. Lechler, G.M. Lord, The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease, Clin Exp Immunol 148 (1) (2007) 32–46.
51. K. Hirota, M. Hashimoto, H. Yoshitomi, S. Tanaka, T. Nomura, T. Yamaguchi, Y. Iwakura, N. Sakaguchi, S. Sakaguchi, T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis, J Exp Med 204 (1) (2007) 41–47.
52. D.M. Roeleveld, M.I. Koenders, The role of the Th17 cytokines IL-17 and IL-22 in Rheumatoid Arthritis pathogenesis and developments in cytokine immunotherapy, Cytokine (2014).
53. B. Bartok, G.S. Firestein, Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis, Immunol Rev 233 (1) (2010) 233–255.